Cite
HARVARD Citation
Li, F. et al. (2017). Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial. Diabetes therapy. 8 (1), pp. 177-187. [Online].